Clinical Sample Logistics and Biostorage

Read: Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM)

Clinical Trials

Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM)

Jun 08, ‘25 | 5 min read

has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778891, hs_child_table_id=0, hs_updated_at=1709645745122, hs_published_at=1748379090824, description=Kurt Preugschat has over 11 years of statistical experience from Phase I to Phase IV clinical trials. He is a lead statistician, providing statistical support and oversight for numerous clinical trials associated with new drug applications (NDA), supplemental new drug applications (sNDA), and medical devices. His expertise includes the development of study designs to meet complex clinical questions and the measurement of desired outcomes. In addition, Kurt has extensive experience generating statistical analyses and creating complex SAS programs and macros used by study team., avatar=Image{width=150,height=150,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/kurt-preugschat.webp',altText='',fileId=null}, linkedin=https://www.linkedin.com/in/kurt-preugschat-97298923a, hs_name=, hs_path=, lastname=Preugschat, hs_initial_published_at=1716136551646, hs_created_at=1709645745122, hs_is_edited=false, hs_deleted_at=0, name=Kurt, job=, slug=kurt-preugschat, email=, hs_updated_by_user_id=51739740}, second={}, third={}})
• 

  Kurt Preugschat

Discover

Read: Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM)

Clinical Trials

Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM)

Jun 06, ‘25 | 5 min read

has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778891, hs_child_table_id=0, hs_updated_at=1709645745122, hs_published_at=1748379090824, description=Kurt Preugschat has over 11 years of statistical experience from Phase I to Phase IV clinical trials. He is a lead statistician, providing statistical support and oversight for numerous clinical trials associated with new drug applications (NDA), supplemental new drug applications (sNDA), and medical devices. His expertise includes the development of study designs to meet complex clinical questions and the measurement of desired outcomes. In addition, Kurt has extensive experience generating statistical analyses and creating complex SAS programs and macros used by study team., avatar=Image{width=150,height=150,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/kurt-preugschat.webp',altText='',fileId=null}, linkedin=https://www.linkedin.com/in/kurt-preugschat-97298923a, hs_name=, hs_path=, lastname=Preugschat, hs_initial_published_at=1716136551646, hs_created_at=1709645745122, hs_is_edited=false, hs_deleted_at=0, name=Kurt, job=, slug=kurt-preugschat, email=, hs_updated_by_user_id=51739740}, second={}, third={}})
• 

  Kurt Preugschat

Discover

Read: Why 100% SDV Is No Longer Feasible — and How Risk-Based Monitoring Saves Time, Money, and Your Trial

Clinical Trials

Why 100% SDV Is No Longer Feasible — and How Risk-Based Monitoring Saves Time, Money, and Your Trial

May 27, ‘25 | 8 min read

has not third author: true, (SizeLimitingPyMap: {main={hs_id=187570680222, hs_child_table_id=0, hs_updated_at=1742413198455, hs_published_at=1748379090824, description=Christine has been ensuring high performance delivery of clinical research projects for more than 23 years. During this time, she has successfully led diverse teams across various cancer indications including renal, pancreatic, melanoma, lung, head and neck, breast, multiple myeloma, extra-nodal NK/T lymphoma, non-Hodgkin’s lymphoma, and Hodgkin’s lymphoma. Within the CRO setting she also supported the strategic development of over 50 hematology/oncology programs including complex Phase 1 projects in immuno-oncology and autologous cell therapy. She also led the establishment of a novel oncology research infrastructure which accelerated study activations for Phase 1 solid tumor studies. Christine obtained her master’s degree in public health at the University of Texas where she also trained in the development and implementation of clinical and epidemiologic research at the Coordinating Center for Clinical Trials as well as the Center for Occupational and Environment Health., avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Christine%20Lusk-1.png',altText='Christine Lusk-1',fileId=187579105870}, lastname=Lusk, hs_initial_published_at=1742410730688, hs_created_by_user_id=26433386, hs_created_at=1742410650472, hs_is_edited=false, hs_deleted_at=0, name=Christine, job=Director, Project Management, slug=christine-lusk, hs_updated_by_user_id=51739740}, second={hs_id=190691157084, hs_child_table_id=0, hs_updated_at=1748379058655, hs_published_at=1748379090824, description=Over the last 15 years, Megan has played a key role in advancing multiple oncology compounds through various stages of development, across numerous tumor types. Having worked at both biotech and CRO companies, Megan brings a comprehensive understanding of clinical operations and drug development. Megan maintains a focus on accelerating the development of innovative cancer therapies to improve patient outcomes worldwide., avatar=Image{width=3024,height=4032,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Megan%20Knoch.jpg',altText='Megan Knoch',fileId=190688034156}, lastname=Knoch, hs_initial_published_at=1748379090824, hs_created_by_user_id=26433386, hs_created_at=1748379018316, hs_is_edited=false, hs_deleted_at=0, name=Megan, slug=megan-knoch, hs_updated_by_user_id=26433386}, third={}})
• 

  Christine L.

• 

  Megan K.

Discover